Cellular senescence refers to a state in which cells permanently stop dividing while remaining metabolically active. It can be triggered by DNA damage, oncogene activation, telomere attrition, oxidative stress, and—inflammatory cytokine signaling. Senescent cells are increasingly recognized as a central contributor to aging biology and to many chronic diseases, not because they are inherently harmful, but because their altered secretory phenotype can disrupt tissue structure and function. The NIH SenNet consortium is focused on identifying and characterizing senescent cells across the human body, spanning the lifespan and distinct health and disease states.
A key concept is the senescence-associated secretory phenotype (SASP). Senescent cells release pro-inflammatory cytokines (such as IL-6 and IL-8), chemokines, growth factors, and extracellular matrix–remodeling enzymes. The SASP can recruit immune cells, reinforce senescence in neighboring cells, and alter local tissue microenvironments. While SASP production may be beneficial early after injury—promoting wound healing and temporarily restraining damaged cell expansion—persistent senescent cell accumulation can drive chronic inflammation, impaired regenerative capacity, vascular dysfunction, fibrosis, and tissue aging. Thus, senescence acts as a double-edged sword: acute or transient senescence can be protective, whereas chronic senescence becomes pathogenic.
Identification of senescent cells in vivo is challenging because senescence is not a single uniform phenotype. Multiple biomarkers exist, but none are universally definitive across all tissues and triggers. Common approaches include detecting senescence-associated beta-galactosidase activity, assessing cell cycle arrest markers such as p16INK4a and p21CIP1/WAF1, and measuring DNA damage responses including persistent gamma-H2AX foci. Transcriptomic signatures capturing SASP programs, proteomic panels, and functional readouts of altered secretions complement marker-based strategies. SenNet’s emphasis on mapping senescent cells across organ systems reflects an important clinical insight: senescent burden and SASP features likely vary with tissue architecture, immune surveillance capacity, and exposure history.
In humans, senescent cells accumulate with age, but the rate and distribution differ between individuals. Factors that accelerate senescence include repeated injury, metabolic stress, radiation exposure, chronic infections, and persistent inflammatory signaling. Conversely, enhanced immune clearance can reduce the persistence of senescent cells. This interplay connects senescence to immunosenescence, where age-associated declines in innate and adaptive immune function can compromise the ability to remove senescent cells. The result is a feedback loop: SASP fuels inflammation, inflammation recruits and exhausts immune components, and reduced clearance permits further senescent accumulation.
From a disease perspective, senescence has been implicated in a spectrum of conditions: atherosclerosis, chronic lung diseases, osteoarthritis, kidney dysfunction, neurodegeneration, and treatment-related morbidities such as radiotherapy- or chemotherapy-associated tissue damage. Mechanistically, SASP-driven inflammation can promote angiogenic dysfunction and vascular remodeling, increase extracellular matrix deposition leading to fibrosis, and interfere with stem/progenitor cell niches. Additionally, senescent cells may influence tumor microenvironments by modulating immune recruitment and affecting extracellular matrix stiffness, potentially impacting tumor progression and response to therapy.
Therapeutically, the senescence field has generated interest in senolytics and senomorphics. Senolytics aim to selectively eliminate senescent cells by targeting survival pathways upregulated in senescent cells. Senomorphics aim to suppress SASP output or other deleterious senescence-associated pathways without necessarily killing the cells. The translational goal is to reduce harmful senescence signaling while preserving potential benefits of transient senescence in tissue repair. However, efficacy and safety depend on accurately measuring senescent burden, confirming target engagement, and understanding tissue-specific senescence biology.
Large, coordinated studies like SenNet help address these requirements by standardizing assays, integrating multi-omics data, and relating senescent cell signatures to clinical phenotypes. Mapping senescent cell states across the lifespan can also clarify whether senescence is merely correlated with age or actively mediates aging-related decline. A major research frontier is defining “senescent cell states” rather than treating senescence as binary. Different triggers may yield distinct SASP profiles, immunogenicity, and metabolic states. Therefore, characterizing senescent cells in diverse contexts—healthy aging versus disease—enables more precise biomarker development and patient stratification.
In summary, cellular senescence is a biologically complex, trigger-dependent program that can contribute to chronic inflammation and tissue deterioration via SASP. The NIH SenNet consortium’s efforts to identify and characterize senescent cells across human tissues, lifespan stages, and disease states are designed to improve biomarker validity, reveal heterogeneity in senescent programs, and ultimately support targeted interventions that mitigate deleterious senescence while preserving physiologic functions. Source: CellPressNews (@CellPressNews) based on the provided Cell Press post referencing NIH SenNet.
Cell Press: Explore the latest research from the NIH SenNet consortium, working to identify and characterize senescent cells across the human body, lifespan, and states of health and disease. @sennetresearch View the collection:. #breaking
— @CellPressNews May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
